Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Different Therapeutic Approaches in Patients With Cardiorenal Syndrome in the Setting of Acute Decompensated Congestive Heart Failure (ADCHF).

Next Previous
Trial Profile

Impact of Different Therapeutic Approaches in Patients With Cardiorenal Syndrome in the Setting of Acute Decompensated Congestive Heart Failure (ADCHF).

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dopamine; Furosemide
  • Indications Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms REWORD-HF

Most Recent Events

  • 10 Apr 2017 Biomarkers information updated
  • 30 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by European Clinical Trials Database record.
  • 07 May 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top